Capsule Summary Slidesets

Share

Program Content

Activities

  • CheckMate 9ER: Subgroup Analyses
    CheckMate 9ER: Efficacy of First-line Nivolumab + Cabozantinib vs Sunitinib in Advanced/Metastatic RCC by Baseline Patient Characteristics
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2021

  • KEYNOTE-052 5-Yr Update
    KEYNOTE-052: 5-Yr Update of First-line Pembrolizumab in Cisplatin-Ineligible Advanced Urothelial Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2021

    Expires: June 10, 2022

  • KEYNOTE-045 5-Yr Update
    KEYNOTE-045: 5-Yr Follow-up of Pembrolizumab in Recurrent Advanced Urothelial Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2021

    Expires: June 10, 2022

  • KEYNOTE 426: Final Analysis
    KEYNOTE-426: Preplanned Final Analysis of First-line Pembrolizumab + Axitinib vs Sunitinib for Advanced Clear-Cell Renal Cell Carcinoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2021

    Expires: June 10, 2022

  • KEYNOTE-564: Adj Pembro in RCC
    KEYNOTE-564: Adjuvant Pembrolizumab vs Placebo After Nephrectomy for Renal Cell Carcinoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 11, 2021

    Expires: June 10, 2022

  • PEACE-3: BPAs and bone health
    Updated Safety Analysis of Fracture Rate With Mandated Bone-Protecting Agents in Phase III EORTC GUCG 1333/PEACE-3 Trial of Enzalutamide ± Radium-223 in mCRPC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 15, 2021

    Expires: June 14, 2022

  • VISION: <sup>177</sup>Lu-PSMA-617 in mCRPC
    VISION: 177Lu-PSMA-617 in Previously Treated Metastatic Castration-Resistant Prostate Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 15, 2021

    Expires: June 14, 2022

  • PEACE-1: Abiraterone in mCSPC
    PEACE-1: Phase III Trial of Abiraterone With or Without Local Radiotherapy + SoC in de novo Metastatic Castration-Sensitive Prostate Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 17, 2021

    Expires: June 16, 2022

Provided by

ProCE Banner

Supporters

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme